Last updated: February 26, 2026
What Is NDC 70000-0334?
NDC 70000-0334 refers to a licensed pharmaceutical product, specifically the Vosevi (sofosbuvir/velpatasvir/voxilaprevir), approved by the FDA for treating hepatitis C virus (HCV) infections. Approved in 2017, Vosevi is indicated for adults with certain genotypes of HCV, especially for those who have failed previous treatment with direct-acting antivirals.
Market Landscape
Current Market Size
The global hepatitis C treatment market is valued at approximately $15 billion in 2022, with major contributions from direct-acting antivirals (DAAs) such as Vosevi. The U.S. accounts for about 60% of the market, with an estimated 2.7 million infected individuals.
Competitor Products
- Mavyret (glecaprevir/pibrentasvir): FDA-approved in 2017, priced at around $26,400 for a 12-week course.
- Harvoni (ledipasvir/sofosbuvir): Launched in 2014, priced at approximately $94,500 for a 12-week course.
- Epclusa (sofosbuvir/velpatasvir): Approved in 2016, priced around $74,760.
Market Penetration
Vosevi targets a niche segment: patients with prior DAA treatment failure. Its market share is growing steadily, especially as resistance and retreatment needs increase.
Key Regulators and Payers
- FDA: Approved Vosevi based on phase 3 trials demonstrating high sustained virologic response (SVR) rates around 96-98% in retreatment cases.
- Medicaid and Medicare: Cover Vosevi with formulary inclusion, though prior authorization and step therapy are common.
- Insurers: Demand on price discounts due to high costs and competing therapies.
Price Trajectory and Projections
Initial Launch Price
- Launch Price (2017): Approximately $74,760 for a 12-week course.
- This aligns with other DAAs' initial pricing, justified by high efficacy and the high cost of drug development.
Year-on-Year Price Trends
Forecasted Price Evolution (Next Five Years)
| Year |
Estimated Price Range (per 12-week course) |
Key Drivers |
| 2023 |
$68,000 - $75,000 |
Negotiations and rebates |
| 2024 |
$65,000 - $72,000 |
Patent expiration considerations |
| 2025 |
$60,000 - $68,000 |
Increasing generic access |
| 2026 |
$55,000 - $65,000 |
Generic formulations available |
| 2027 |
$50,000 - $60,000 |
Market penetration, price compression |
Impact of Patent Expiration and Generics
The patent for Vosevi extends until approximately 2032 (assuming no extensions). As biosimilars and generics enter the market after patent expiry, prices are expected to decline significantly, possibly by 50-70%. In the short term, negotiations may bring discounts, but the presence of less expensive alternatives will alter the pricing landscape.
Key Factors Influencing Price and Market Share
- Patent Protection: Firm until 2032; patent challenges could accelerate generic entry.
- Pricing Negotiation Power: Payers and PBMs push for rebates; this influences net price more than list price.
- Regulatory Approvals: Expanded indications could increase patient access, raising sales volume.
- Market Penetration Strategy: Expansion in emerging markets could impact revenue, though price controls are prevalent.
- Cost Efficiency: Manufacturing costs for Vosevi remain stable, but competition pressures may reduce margins.
Revenue Projections
Based on current market penetration and pricing strategies, revenue estimates are:
| Year |
Estimated Revenue (USD billions) |
Assumptions |
| 2023 |
$1.2 |
15% market share in the retreatment segment |
| 2024 |
$1.4 |
Increased use due to resistance issues |
| 2025 |
$1.6 |
Expanded indications and geographic reach |
| 2026 |
$1.8 |
Entry of generics reduces average price |
| 2027 |
$1.5 |
Market saturation and pricing competition |
Key Takeaways
- Vosevi represents a premium priced drug with high efficacy for difficult-to-treat HCV cases.
- Pricing has remained stable post-launch, with modest decreases due to negotiations.
- Future price declines will accelerate following patent expiry and generic entry around 2032.
- The total market remains robust, driven by unmet needs and retreatment cases.
- Strategic pricing, reimbursement negotiations, and patent protections will shape revenue and market positioning over the next decade.
FAQs
1. What factors determine the future price of Vosevi?
Patent status, competition from generics, negotiated rebates, and regulatory changes influence future pricing.
2. How does Vosevi compare to other hepatitis C treatments in cost?
Vosevi’s initial price is comparable or slightly higher than other second-line treatments like Epclusa but offers advantages in retreatment scenarios.
3. Will generic versions significantly reduce prices?
Yes, generic entry post-2032 is projected to reduce prices by 50-70%, similar to patterns observed with other DAAs.
4. How does market penetration impact revenue?
Increased use, especially among retreatment patients, will drive revenue growth until market saturation occurs.
5. What payers are likely to negotiate the most favorable prices?
Medicaid programs and large health insurers with high negotiating leverage typically secure the largest rebates and discounts.
References
[1] FDA (2017). Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Prescribing Information.
[2] MarketWatch (2022). Global hepatitis C market size.
[3] IQVIA (2022). U.S. hepatitis C therapeutic sales data.
[4] Food and Drug Administration (2022). Patent and exclusivity status of hepatitis C drugs.
[5] CMS (2022). Medicare coverage policies for hepatitis C therapies.
